Instrument Inactif

Communiqués Checkmate Pharmaceuticals, Inc.

Actions

CMPI

US1628181083

Recherche biotechnologique et médicale

Communiqués

31/05/22	Checkmate Pharmaceuticals : Completion of Acquisition or Disposition of Assets - Form 8-K	PU
31/05/22	CHECKMATE PHARMACEUTICALS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
26/05/22	University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting	AQ
26/05/22	University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting	GL
17/05/22	CHECKMATE PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkmate Pharmaceuticals, Inc. - CMPI	BU
12/05/22	CHECKMATE PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
12/05/22	Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update	AQ
12/05/22	Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update	GL
06/05/22	CHECKMATE PHARMACEUTICALS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkmate Pharmaceuticals, Inc. - CMPI	BU
19/04/22	Checkmate Pharmaceuticals : TENDER AND SUPPORT AGREEMENT - Form 8-K	PU
19/04/22	CHECKMATE PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
19/04/22	Checkmate Pharmaceuticals : Joint Press Release, issued April 19, 2022 - Form 8-K	PU
19/04/22	CHECKMATE PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
19/04/22	Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types	PR
08/04/22	Checkmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research (AACR) Annual Meeting	AQ
30/03/22	Checkmate Pharmaceuticals : Announces Full Year 2021 Financial Results and Provides Business Update - Form 8-K	PU
30/03/22	CHECKMATE PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
29/03/22	Checkmate Pharmaceuticals Announces Full Year 2021 Financial Results and Provides Business Update	GL
29/03/22	Checkmate Pharmaceuticals Announces Full Year 2021 Financial Results and Provides Business Update	GL
08/03/22	Checkmate Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting	GL
08/03/22	Checkmate Pharmaceuticals : Corporate Overview – March 2022	PU
01/03/22	CHECKMATE PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
15/02/22	Checkmate Pharmaceuticals : Corporate Overview – February 2022	PU
09/02/22	Checkmate Pharmaceuticals : Appoints Alan Bash as President and CEO - Form 8-K	PU
09/02/22	CHECKMATE PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ